Oxford Vacmedix Raises £3M to Make Vaccines More Powerful and Cheaper to Produce
November 6, 2024
Oxford Vacmedix, a vaccine technology company based at the University of Oxford's research ecosystem, has raised £3 million from Prostate Cancer Research, the Dx&Vx venture fund, and business angels to advance its platform for improving vaccine potency and reducing production costs. The company is developing a proprietary technology platform that enhances how effectively vaccines stimulate the immune system — increasing immunogenicity — while at the same time simplifying and reducing the cost of the manufacturing processes needed to produce vaccine doses at scale.
These two goals — higher potency and lower manufacturing cost — have historically been in tension in vaccine development. More potent vaccines often require more complex formulations, purification processes, or adjuvant systems that add manufacturing overhead. Oxford Vacmedix's platform addresses both simultaneously through a technology that modifies the presentation of vaccine antigens — the molecular components that train the immune system to recognise a pathogen or tumour — in a way that produces stronger, more durable immune responses without requiring more complex or expensive production chemistry.
The applications span both cancer vaccines and infectious disease. In oncology, the company's initial focus is prostate cancer, which is reflected in the backing from Prostate Cancer Research — a UK charity that funds research into better diagnosis and treatment of the disease, which affects more than 52,000 men annually in the UK. Therapeutic cancer vaccines represent a long-sought goal in immunotherapy: the ability to train a patient's immune system to recognise and attack cancer cells specifically. While most cancer immunotherapy to date has used immune checkpoint inhibitors, personalised cancer vaccines are an area of intensifying research interest following promising clinical data in melanoma and other tumour types. Improved vaccine potency platforms like Oxford Vacmedix's could expand the range of cancer types in which therapeutic vaccination becomes clinically viable.
The funding will support continued development of the platform technology, preclinical validation across multiple vaccine applications, and partnership discussions with pharmaceutical companies and cancer research institutions seeking improved vaccine formulation capabilities.
Sources
Thank you to our Patrons & Partners:
